(Boursier.com) — The biotechnology company MaaT Pharmaa leader in the development of Microbiome Ecosystem Therapies (MET) aimed at improving the survival of cancer patients, presents at the 2024 American Association for Cancer Research (AACR) Annual Conference in San Diego, California , new in vitro data characterizing the metabolites produced by MaaT034 and their impacts on immune modulation.
The published data represent significant advances in understanding the mechanism of action (MoA) of co-cultured microbial therapies developed by MaaT Pharma, marking an important step towards clinical evaluation. The results demonstrate that MaaT034 produced key metabolites known to promote intestinal barrier restoration and modulate immune responses, such as short-chain fatty acids (SCFAs), secondary bile acids and tryptophan derivatives. These data confirm the role of MaaT034 in the repair of the intestinal barrier and in the reactivation of T cells, whether in combination with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1). By improving the repair of the intestinal barrier and modulating the immune response, MaaT034 could thus complement the action of these immunotherapeutic agents, potentially improving their effectiveness in the treatment of solid tumor cancers.
The first study in humans is planned for 2025.
Recall that MaaT034, the first product of MaaT Pharma’s MET-C platform, is composed of innovative synthetic microbiota and equipped with a complete ecosystem, developed in combination with immune checkpoint inhibitors to improve the effectiveness of treatments in solid tumors, a large market. The MET-C platform allows MaaT Pharma to produce microbiota-derived therapies on a large scale to meet the needs of large-market indications.
©2024 Boursier.com